These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17164314)

  • 1. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
    Antoniucci DM; Sellmeyer DE; Bilezikian JP; Palermo L; Ensrud KE; Greenspan SL; Black DM
    J Clin Endocrinol Metab; 2007 Mar; 92(3):942-7. PubMed ID: 17164314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.
    Miller PD; Bilezikian JP; Diaz-Curiel M; Chen P; Marin F; Krege JH; Wong M; Marcus R
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3535-41. PubMed ID: 17609307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study.
    Piemonte S; Romagnoli E; Cipriani C; Fassino V; Del Fiacco R; Carnevale V; Scillitani A; D'Erasmo E; Tancredi A; Minisola S
    Calcif Tissue Int; 2009 Oct; 85(4):287-92. PubMed ID: 19756348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of hypercalcemia, hypercalciuria and related factors in patients treated with recombinant human parathyroid hormone (1-84).
    Luna-Cabrera F; Justicia-Rull EA; Caricol-Pérez MP; Soler-Vizán E; Mesa-López CM; Ruiz-Ruiz MA; De La Torre-López LE
    Minerva Med; 2012 Apr; 103(2):103-10. PubMed ID: 22513515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.
    Schafer AL; Palermo L; Bauer DC; Bilezikian JP; Sellmeyer DE; Black DM
    J Clin Densitom; 2011; 14(1):68-73. PubMed ID: 21095149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
    Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
    Binkley N; Ringe JD; Reed JI; Ljunggren O; Holick MF; Minne HW; Liu M; Lamotta A; West JA; Santora AC
    Bone; 2009 Apr; 44(4):639-47. PubMed ID: 19185560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
    Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
    BMC Musculoskelet Disord; 2018 Jul; 19(1):210. PubMed ID: 29970059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
    Sellmeyer DE; Black DM; Palermo L; Greenspan S; Ensrud K; Bilezikian J; Rosen CJ
    Osteoporos Int; 2007 Jul; 18(7):973-9. PubMed ID: 17333451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
    Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant full-length parathyroid hormone (1-84).
    Moen MD; Scott LJ
    Drugs; 2006; 66(18):2371-81; discussion 2382-5. PubMed ID: 17181378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
    Shapses SA; Kendler DL; Robson R; Hansen KE; Sherrell RM; Field MP; Woolf E; Berd Y; Mantz AM; Santora AC
    J Bone Miner Res; 2011 Aug; 26(8):1836-44. PubMed ID: 21448918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria.
    Pak CY; Oata M; Lawrence EC; Snyder W
    J Clin Invest; 1974 Aug; 54(2):387-400. PubMed ID: 4367891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
    Giampà E; Di Bonito M; Ferretti V; Nuvoli G; Paoletti F; Piazzini M; Ranieri M; Tuveri MA; Vinicola V
    Minerva Endocrinol; 2019 Dec; 44(4):344-350. PubMed ID: 31971357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women.
    Gallagher JC; Smith LM; Yalamanchili V
    Menopause; 2014 Nov; 21(11):1173-80. PubMed ID: 24937025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
    Park JH; Park KH; Cho S; Choi YS; Seo SK; Lee BS; Park HS
    Menopause; 2013 Jul; 20(7):747-53. PubMed ID: 23511701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.